The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Metabolic Disease Therapeutics Market Research Report 2025
Synopsis
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
The global Metabolic Disease Therapeutics market was valued at US$ 82150 million in 2023 and is anticipated to reach US$ 160970 million by 2030, witnessing a CAGR of 10.1% during the forecast period 2024-2030.
The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disease Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disease Therapeutics.
Report Scope
The Metabolic Disease Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metabolic Disease Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metabolic Disease Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Segment by Type
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabolic Disease Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
The global Metabolic Disease Therapeutics market was valued at US$ 82150 million in 2023 and is anticipated to reach US$ 160970 million by 2030, witnessing a CAGR of 10.1% during the forecast period 2024-2030.
The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disease Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disease Therapeutics.
Report Scope
The Metabolic Disease Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metabolic Disease Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metabolic Disease Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Segment by Type
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabolic Disease Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disease Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Market by Application
1.3.1 Global Metabolic Disease Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disease Therapeutics Market Perspective (2019-2030)
2.2 Metabolic Disease Therapeutics Growth Trends by Region
2.2.1 Global Metabolic Disease Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Metabolic Disease Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Metabolic Disease Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Metabolic Disease Therapeutics Market Dynamics
2.3.1 Metabolic Disease Therapeutics Industry Trends
2.3.2 Metabolic Disease Therapeutics Market Drivers
2.3.3 Metabolic Disease Therapeutics Market Challenges
2.3.4 Metabolic Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disease Therapeutics Players by Revenue
3.1.1 Global Top Metabolic Disease Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Metabolic Disease Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Metabolic Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disease Therapeutics Revenue
3.4 Global Metabolic Disease Therapeutics Market Concentration Ratio
3.4.1 Global Metabolic Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disease Therapeutics Revenue in 2023
3.5 Metabolic Disease Therapeutics Key Players Head office and Area Served
3.6 Key Players Metabolic Disease Therapeutics Product Solution and Service
3.7 Date of Enter into Metabolic Disease Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disease Therapeutics Breakdown Data by Type
4.1 Global Metabolic Disease Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Metabolic Disease Therapeutics Forecasted Market Size by Type (2025-2030)
5 Metabolic Disease Therapeutics Breakdown Data by Application
5.1 Global Metabolic Disease Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Metabolic Disease Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Metabolic Disease Therapeutics Market Size (2019-2030)
6.2 North America Metabolic Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Metabolic Disease Therapeutics Market Size by Country (2019-2024)
6.4 North America Metabolic Disease Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metabolic Disease Therapeutics Market Size (2019-2030)
7.2 Europe Metabolic Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Metabolic Disease Therapeutics Market Size by Country (2019-2024)
7.4 Europe Metabolic Disease Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disease Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Metabolic Disease Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Metabolic Disease Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Metabolic Disease Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metabolic Disease Therapeutics Market Size (2019-2030)
9.2 Latin America Metabolic Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Metabolic Disease Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Metabolic Disease Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disease Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Metabolic Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Metabolic Disease Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Metabolic Disease Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Metabolic Disease Therapeutics Introduction
11.1.4 Merck Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Metabolic Disease Therapeutics Introduction
11.2.4 Novartis Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Takeda Pharmaceutical
11.3.1 Takeda Pharmaceutical Company Detail
11.3.2 Takeda Pharmaceutical Business Overview
11.3.3 Takeda Pharmaceutical Metabolic Disease Therapeutics Introduction
11.3.4 Takeda Pharmaceutical Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.3.5 Takeda Pharmaceutical Recent Development
11.4 Astra Zeneca
11.4.1 Astra Zeneca Company Detail
11.4.2 Astra Zeneca Business Overview
11.4.3 Astra Zeneca Metabolic Disease Therapeutics Introduction
11.4.4 Astra Zeneca Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.4.5 Astra Zeneca Recent Development
11.5 Beohrigher Ingelheim
11.5.1 Beohrigher Ingelheim Company Detail
11.5.2 Beohrigher Ingelheim Business Overview
11.5.3 Beohrigher Ingelheim Metabolic Disease Therapeutics Introduction
11.5.4 Beohrigher Ingelheim Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.5.5 Beohrigher Ingelheim Recent Development
11.6 KOWA
11.6.1 KOWA Company Detail
11.6.2 KOWA Business Overview
11.6.3 KOWA Metabolic Disease Therapeutics Introduction
11.6.4 KOWA Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.6.5 KOWA Recent Development
11.7 Kythera
11.7.1 Kythera Company Detail
11.7.2 Kythera Business Overview
11.7.3 Kythera Metabolic Disease Therapeutics Introduction
11.7.4 Kythera Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.7.5 Kythera Recent Development
11.8 Fuji yakuhin
11.8.1 Fuji yakuhin Company Detail
11.8.2 Fuji yakuhin Business Overview
11.8.3 Fuji yakuhin Metabolic Disease Therapeutics Introduction
11.8.4 Fuji yakuhin Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.8.5 Fuji yakuhin Recent Development
11.9 LG Life Science
11.9.1 LG Life Science Company Detail
11.9.2 LG Life Science Business Overview
11.9.3 LG Life Science Metabolic Disease Therapeutics Introduction
11.9.4 LG Life Science Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.9.5 LG Life Science Recent Development
11.10 Metsubishi Tanabe Pharma
11.10.1 Metsubishi Tanabe Pharma Company Detail
11.10.2 Metsubishi Tanabe Pharma Business Overview
11.10.3 Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Introduction
11.10.4 Metsubishi Tanabe Pharma Revenue in Metabolic Disease Therapeutics Business (2019-2024)
11.10.5 Metsubishi Tanabe Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Metabolic Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Glycogen Metabolism Disease Drug
Table 3. Key Players of Lipid Metabolism Disease Drug
Table 4. Key Players of Amino Acid Metabolism Drug
Table 5. Key Players of Other
Table 6. Global Metabolic Disease Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Metabolic Disease Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Metabolic Disease Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Metabolic Disease Therapeutics Market Share by Region (2019-2024)
Table 10. Global Metabolic Disease Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Metabolic Disease Therapeutics Market Share by Region (2025-2030)
Table 12. Metabolic Disease Therapeutics Market Trends
Table 13. Metabolic Disease Therapeutics Market Drivers
Table 14. Metabolic Disease Therapeutics Market Challenges
Table 15. Metabolic Disease Therapeutics Market Restraints
Table 16. Global Metabolic Disease Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Metabolic Disease Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Metabolic Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Therapeutics as of 2023)
Table 19. Ranking of Global Top Metabolic Disease Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Metabolic Disease Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Metabolic Disease Therapeutics Product Solution and Service
Table 23. Date of Enter into Metabolic Disease Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metabolic Disease Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Metabolic Disease Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Metabolic Disease Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Metabolic Disease Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Metabolic Disease Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Metabolic Disease Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Metabolic Disease Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Metabolic Disease Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Metabolic Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Metabolic Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Metabolic Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Metabolic Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Metabolic Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Metabolic Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Metabolic Disease Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Metabolic Disease Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Metabolic Disease Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Metabolic Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Metabolic Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Metabolic Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Metabolic Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Metabolic Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Metabolic Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Merck Company Detail
Table 49. Merck Business Overview
Table 50. Merck Metabolic Disease Therapeutics Product
Table 51. Merck Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 52. Merck Recent Development
Table 53. Novartis Company Detail
Table 54. Novartis Business Overview
Table 55. Novartis Metabolic Disease Therapeutics Product
Table 56. Novartis Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. Takeda Pharmaceutical Company Detail
Table 59. Takeda Pharmaceutical Business Overview
Table 60. Takeda Pharmaceutical Metabolic Disease Therapeutics Product
Table 61. Takeda Pharmaceutical Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Takeda Pharmaceutical Recent Development
Table 63. Astra Zeneca Company Detail
Table 64. Astra Zeneca Business Overview
Table 65. Astra Zeneca Metabolic Disease Therapeutics Product
Table 66. Astra Zeneca Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 67. Astra Zeneca Recent Development
Table 68. Beohrigher Ingelheim Company Detail
Table 69. Beohrigher Ingelheim Business Overview
Table 70. Beohrigher Ingelheim Metabolic Disease Therapeutics Product
Table 71. Beohrigher Ingelheim Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 72. Beohrigher Ingelheim Recent Development
Table 73. KOWA Company Detail
Table 74. KOWA Business Overview
Table 75. KOWA Metabolic Disease Therapeutics Product
Table 76. KOWA Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 77. KOWA Recent Development
Table 78. Kythera Company Detail
Table 79. Kythera Business Overview
Table 80. Kythera Metabolic Disease Therapeutics Product
Table 81. Kythera Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Kythera Recent Development
Table 83. Fuji yakuhin Company Detail
Table 84. Fuji yakuhin Business Overview
Table 85. Fuji yakuhin Metabolic Disease Therapeutics Product
Table 86. Fuji yakuhin Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 87. Fuji yakuhin Recent Development
Table 88. LG Life Science Company Detail
Table 89. LG Life Science Business Overview
Table 90. LG Life Science Metabolic Disease Therapeutics Product
Table 91. LG Life Science Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 92. LG Life Science Recent Development
Table 93. Metsubishi Tanabe Pharma Company Detail
Table 94. Metsubishi Tanabe Pharma Business Overview
Table 95. Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Product
Table 96. Metsubishi Tanabe Pharma Revenue in Metabolic Disease Therapeutics Business (2019-2024) & (US$ Million)
Table 97. Metsubishi Tanabe Pharma Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disease Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Metabolic Disease Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Glycogen Metabolism Disease Drug Features
Figure 4. Lipid Metabolism Disease Drug Features
Figure 5. Amino Acid Metabolism Drug Features
Figure 6. Other Features
Figure 7. Global Metabolic Disease Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Metabolic Disease Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Metabolic Disease Therapeutics Report Years Considered
Figure 12. Global Metabolic Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Metabolic Disease Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Metabolic Disease Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Metabolic Disease Therapeutics Market Share by Players in 2023
Figure 16. Global Top Metabolic Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Metabolic Disease Therapeutics Revenue in 2023
Figure 18. North America Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Metabolic Disease Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Metabolic Disease Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Metabolic Disease Therapeutics Market Share by Region (2019-2030)
Figure 32. China Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Metabolic Disease Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Metabolic Disease Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Metabolic Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Merck Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 47. Novartis Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 48. Takeda Pharmaceutical Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 49. Astra Zeneca Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 50. Beohrigher Ingelheim Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 51. KOWA Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 52. Kythera Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 53. Fuji yakuhin Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 54. LG Life Science Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 55. Metsubishi Tanabe Pharma Revenue Growth Rate in Metabolic Disease Therapeutics Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
